Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 46

recruiting
3 972
countries
28
conditions
2 103

824 trials match your criteria

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

Hormone-refractory prostate cancer

Not recruiting

Study of Cabozantinib and Atezolizumab Compared to Hormonal Therapy in Adults with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Cardiac amyloidosis

Not recruiting

Study on the Safety of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy Who Completed a Previous Trial

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride

Gastric cancer+2

Not recruiting

Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Partial seizures

Not recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab

Interstitial lung disease

Not recruiting

Study on the Long-Term Safety of Nintedanib for Children and Adolescents with Interstitial Lung Disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Nintedanib

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid

Multiple system atrophy

Not recruiting

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Saline

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.